On Air Now

Listen

Listen Live Now » 101.1 FM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
70° Feels Like: 70°
Wind: W 8 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Today

Thunderstorms 76°

Tonight

Clear 56°

Tomorrow

Mostly Sunny 77°

Alerts

Galapagos, GSK successfully conclude phase 2a study of skin disease drug

The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor
The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor

BRUSSELS (Reuters) - Belgian biotech group Galapagos NV on Thursday said it has successfully concluded the phase 2a study of a skin disease drug it is developing with Britain's GlaxoSmithKline PLC.

Galapagos tested drug GSK2586184 on 66 patients with chronic psoriasis and observed a 75 percent improvement in significantly more patients than in the placebo group.

GSK, which owns the drug's commercial rights, will decide whether to proceed with clinical trials, Galapagos said in a statement.

Galapagos said it could receive a milestone payment of up to 34 million euros ($46.94 million) as well as double-digit royalties as the program proceeds towards commercialization.

($1 = 0.7243 Euros)

(Reporting by Robert-Jan Bartunek; Editing by Christopher Cushing)

Comments